<DOC>
	<DOCNO>NCT02121353</DOCNO>
	<brief_summary>The aim study test PF582 ( ranibizumab ) safe similar Lucentis ( ranibizumab ) . Participants screen visit check eligibility . Eligible participant receive either PF582 Lucentis , injection one eye study Day 1 , 28 56 . Visits conduct Day 2 , 7 , 14 80 6 12 month . During study participant undergo follow procedure : height , weight vital sign ( blood pressure , pulse , temperature , breathe rate ) measurement ; medical surgical history concomitant medication ; adverse event monitoring ; physical examination ; eye test ( read chart , measurement retinal thickness [ via picture retina ] examination eye 's blood vessel , via picture take follow injection dye arm ) , blood collection urine pregnancy test , applicable .</brief_summary>
	<brief_title>Safety Study PF582 Versus Lucentis Patients With Age Related Macular Degeneration</brief_title>
	<detailed_description>To evaluate safety tolerability PF582 , compare Lucentis ( register trademark ) patient neovascular AMD . This do assessment vital sign , physical examination , laboratory blood test adverse event . Possible adverse event include : eye irritation/discomfort , redness/itching eye , eye dryness , abnormal sensation eye ; lens clouding ; pain/irritation injection site ; increase tear production ; 'floaters ' ; sore throat , nasal congestion , headache , joint pain , flu , fatigue , breathlessness , dizziness , pale skin , anxiety , cough , nausea allergic reaction . Because PF582 similar Lucentis expect similar adverse effect .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥50 year Presence study eye ( one eye per patient ) previously untreated active subfoveal CNV due AMD , presence leakage , see FA , fluid , see spectral‐domain OCT , locate either within retina , retinal pigment epithelium Visual acuity 20/25 20/320 measure use Early treatment diabetic retinopathy study ( ETDRS ) protocol1 ( chart 4 meter ) pupil dilation . Neovascularization , fluid , haemorrhage fovea . Fibrosis &lt; 50 % total lesion area At least 1 drusen ( &gt; 63μm ) either eye late AMD fellow eye . Female subject must non‐childbearing potential , meet least one follow criterion : Amenorrheal 12 month ( Menopause confirm FSH LH level define establish reference range ) , take oral contraception least 3 month , surgically sterile least past 3 month , Receiving stable dose implant injectable contraceptive least 3 month Previous treatment CNV study eye , include antivascular endothelial growth factor ( VEGF ) medication Other progressive retinal disease study eye , non‐study eye , likely compromise Visual Acuity assessment . Contraindications injection Lucentis® Sub‐retineal Haemorrhage &gt; 50 % lesion Fibrosis retrofoveolar atrophy History retrofoveolar laser photocoagulation Previous Lucentis® treatment Any treatment ( photocoagulation , phototherapy , radiotherapy , surgery , thermotherapy ) last 3 month Aphaky , vitrectomy Active suspect ocular periocular infection Active intraocular inflammation Active systemic infection History stroke congestive heart failure Any clinical significant illness abnormality would compromise safety participant Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Age relate macular degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Eye condition</keyword>
	<keyword>CFT</keyword>
	<keyword>OCT</keyword>
	<keyword>CNV</keyword>
	<keyword>FA</keyword>
	<keyword>Ocular</keyword>
	<keyword>Eye</keyword>
	<keyword>Disorder eye</keyword>
</DOC>